AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7798503 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with streptokinase, recombinant tissue-type plasminogen activator, or anistreplase plus intravenous heparin (5,000 IU bolus followed by 1,000 U/h infusion)
Number of subjects: 43
Study 2119263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator
Number of subjects: 655
Study 2119263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 6118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene preparation (Doleron novum)
Number of subjects: 94
Study 6118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine preparation (Staralgin)
Number of subjects: 94
Study 6118380 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 94
Study 31767717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g oral fosfomycin tromethamine every other day (QOD) for 3 doses and then every day (QD) for 7 doses
Number of subjects: 18
Study 27860267 — intervention group
Group type: EXPERIMENTAL
Intervention: RN317 (s.c. 3.0 mg/kg)
Number of subjects: 133
Study 27860267 — intervention group
Group type: COMPARATOR
Intervention: Bococizumab (s.c. 3.0 mg/kg)
Number of subjects: 133
Study 27860267 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose RN317 (s.c. 300 mg every 28 days; three doses)
Number of subjects: 133
Study 24967824 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Tranexamic acid (TXA) postoperatively, diluted to 0.2% concentration, gargled or sprayed 5-6 times daily from postoperative day 5-10.
Number of subjects: 494
Study 24967824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA application)
Number of subjects: 494
Study 24967824 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Tranexamic acid (TXA) postoperatively
Number of subjects: 494
Study 23110312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibermalt 45 g/d
Number of subjects: 29
Study 23110312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibermalt 60 g/d
Number of subjects: 29
Study 23110312 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g/d)
Number of subjects: 29
Study 21859366 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(III) polymaltose complex (Maltofer(®)) 100 mg iron twice daily for 90 days
Number of subjects: 80
Study 21859366 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate 100 mg iron twice daily for 90 days
Number of subjects: 80
Study 19057424 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery (RS)
Number of subjects: 21
Study 19057424 — intervention group
Group type: COMPARATOR
Intervention: Non-radiated (RS)
Number of subjects: 21
Study 16897119 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation program
Number of subjects: 50
Study 16897119 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback‐assisted isometric exercises
Number of subjects: 50
Study 15215110 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL5788 (750 mg)
Number of subjects: 40
Study 15215110 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL5788 (125, 250, 500, 750, and 1,000 mg)
Number of subjects: 40
Study 15215110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11521989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (400 mg b.i.d.)
Number of subjects: 55
Study 11521989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9670986 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 9670986 — intervention group
Group type: COMPARATOR
Intervention: Nonsensitized controls
Number of subjects: 0
Study 8168039 — intervention group
Group type: COMPARATOR
Intervention: CMF regimen (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Number of subjects: 163
Study 8168039 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-CMF (CMF preceded by diethylstilbestrol 1 mg orally per day for 3 days)
Number of subjects: 163
Study 3233520 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour teacher training workshop on child sexual abuse prevention
Number of subjects: 45
Study 3233520 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-only vignettes measure
Number of subjects: 45
Study 3233520 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week follow-up period
Number of subjects: 45
Study 3233520 — intervention group
Group type: COMPARATOR
Intervention: Behavioral dimensions (reporting suspected abuse cases)
Number of subjects: 45
Study 31077751 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D tablet, 1000IU/day (N=180; 69 boys, 111 girls)
Number of subjects: 535
Study 31077751 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified milk consumption, 200 ml/day, 40IU/100 ml (N=189; 93 boys, 96 girls)
Number of subjects: 535
Study 31077751 — intervention group
Group type: COMPARATOR
Intervention: Control (educational awareness) (N=166; 81 boys, 85 girls)
Number of subjects: 535
Study 28865716 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone maintenance treatment for 1 year
Number of subjects: 374
Study 28865716 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment length
Number of subjects: 374
Study 28865716 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness
Number of subjects: 374
Study 28865716 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline remission patients
Number of subjects: 374
Study 25878120 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of imatinib combined with reduced-intensity chemotherapy (arm A)
Number of subjects: 268
Study 25878120 — intervention group
Group type: COMPARATOR
Intervention: Standard imatinib/hyperCVAD therapy (arm B)
Number of subjects: 268
Study 25878120 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 268
Study 23568000 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention (n = 68)
Number of subjects: 138
Study 23568000 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 138
Study 23568000 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 58)
Number of subjects: 138
Study 21422934 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastoplast bandaging
Number of subjects: 0
Study 21422934 — intervention group
Group type: EXPERIMENTAL
Intervention: Double tubigrip bandage
Number of subjects: 0
Study 21422934 — intervention group
Group type: EXPERIMENTAL
Intervention: No support
Number of subjects: 0
Study 18424596 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallot flesh (99.2% quercetin glucosides and 0.8% quercetin aglycone)
Number of subjects: 9
Study 18424596 — intervention group
Group type: COMPARATOR
Intervention: Dry shallot skin (83.3% quercetin aglycone and 16.7% quercetin glucosides)
Number of subjects: 9
Study 16877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 112.5 IU recombinant FSH from cycle day 2-6 (Group A)
Number of subjects: 0
Study 16877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 112.5 IU recombinant FSH from cycle day 7-11 (Group B)
Number of subjects: 0
Study 16877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (CD 2-6)
Number of subjects: 0
Study 16877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (CD 7-11)
Number of subjects: 0
Study 12508146 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14 antibody)
Number of subjects: 16
Study 12508146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11789188 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM-WM group
Number of subjects: 48
Study 11789188 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy group
Number of subjects: 48
Study 11789188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 8829932 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia with nitrous oxide (induced with thiopentone 6 mg kg‐1, maintained with halothane 1% and nitrous oxide 66% in oxygen)
Number of subjects: 50
Study 8829932 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia with propofol-alfentanil (induced with alfentanil 25 micrograms kg‐1 and propofol 2 mg kg‐1, maintained with alfentanil and propofol infusions)
Number of subjects: 50
Study 2056774 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin (ACR) 75 mg/m2 daily for 3 days plus cytosine arabinoside (ara‐C) 100 mg/m2 per day for 7 days
Number of subjects: 180
Study 2056774 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 45 mg/m2/day for 3 days plus ara‐C for 7 days
Number of subjects: 180
Study 2056774 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin (ACR) plus ara‐C
Number of subjects: 180
Study 2056774 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) plus ara‐C
Number of subjects: 180
Study 6601847 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfadimidine (1 g four times daily for seven days)
Number of subjects: 151
Study 6601847 — intervention group
Group type: EXPERIMENTAL
Intervention: tetracycline (500 mg four times daily for seven days)
Number of subjects: 151
Study 6601847 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole (TMP‐SMZ; 160 mg of TMP and 800 mg of SMZ twice daily for seven days)
Number of subjects: 151
Study 6601847 — intervention group
Group type: EXPERIMENTAL
Intervention: doxycycline (300 mg as a single dose)
Number of subjects: 151
Study 6601847 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP‐sulfametrole (640 mg of TMP and 3,200 mg of sulfametrole once as a single dose)
Number of subjects: 151
Study 30032464 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based upper airway exercises (15 min of daily gameplay)
Number of subjects: 16
Study 30032464 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 s of daily voice recording)
Number of subjects: 16
Study 30032464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 16
Study 30032464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 28115223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Rotacaps/Rotahaler
Number of subjects: 0
Study 28115223 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Diskus
Number of subjects: 0
Study 28115223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via either inhaler
Number of subjects: 0
Study 26769830 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossFit training for 3 months
Number of subjects: 0
Study 24268861 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin
Number of subjects: 14641
Study 24268861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study 21121981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 5.0 × 10⁷ CFU/g, daily intake of 3.4 × 10⁹ CFU for 3 months
Number of subjects: 39
Study 21121981 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LGG)
Number of subjects: 39
Study 21121981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 39
Study 19415672 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 124
Study 19415672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Number of subjects: 124
Study 17451506 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF/SnF(2)) mouthrinse used daily for 3 weeks
Number of subjects: 30
Study 15844402 — intervention group
Group type: COMPARATOR
Intervention: Anorexic patients
Number of subjects: 11
Study 15844402 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 11
Study 11386644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/mL applied intraoperatively for 5 minutes)
Number of subjects: 16
Study 11386644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mitomycin C)
Number of subjects: 16
Study 9893104 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples drawn on Mondays
Number of subjects: 209
Study 9893104 — intervention group
Group type: COMPARATOR
Intervention: Blood samples drawn on non-Mondays
Number of subjects: 209
Study 9893104 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants starting and ending on a Monday
Number of subjects: 209
Study 9893104 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who changed the day of examination from Monday to non-Monday or vice versa
Number of subjects: 209
Study 8038981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol 10 mg (group I)
Number of subjects: 50
Study 8038981 — intervention group
Group type: COMPARATOR
Intervention: 1 ml intralipid (group II)
Number of subjects: 50
Study 2740681 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Ceftriaxone (2 grams)
Number of subjects: 0
Study 2740681 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (multiple doses)
Number of subjects: 0
Study 1221098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic therapy
Number of subjects: 0
Study 1221098 — intervention group
Group type: COMPARATOR
Intervention: Drug induced hypotension
Number of subjects: 0
Study 1221098 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (drug induced hypotension and antifibrinolytic therapy)
Number of subjects: 0
Study 31521682 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + optimal medical therapy
Number of subjects: 1212
Study 31521682 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 1212
Study 28339282 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin with olanzapine and lithium carbonate
Number of subjects: 48
Study 28339282 — intervention group
Group type: COMPARATOR
Intervention: Placebo with olanzapine and lithium carbonate
Number of subjects: 48
Study 25290104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloidal vibration therapy applied to the knee extensors twice daily for 7 days
Number of subjects: 50
Study 25290104 — intervention group
Group type: COMPARATOR
Intervention: Stretching and sports massage (SSM) performed twice daily for 7 days
Number of subjects: 50
Study 23272987 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness therapy
Number of subjects: 119
Study 23272987 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 119
Study 23272987 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness therapy and Enhanced treatment as usual
Number of subjects: 119
Study 23272987 — intervention group
Group type: COMPARATOR
Intervention: BDS patients
Number of subjects: 119
Study 21480731 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 40
Study 21480731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18022787 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal consent (n = 100)
Number of subjects: 300
Study 18022787 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited written consent (n = 100)
Number of subjects: 300
Study 18022787 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed written consent with signature (n = 100)
Number of subjects: 300
Study 16412159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 0
Study 16412159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 0
Study 16412159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 0
Study 16412159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12897045 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (beta-carotene: 6 mg, vitamin C: 120 mg, vitamin E: 30 mg, zinc: 20 mg, selenium: 100 micro g)
Number of subjects: 106
Study 12897045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 12897045 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 106
Study 10726050 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 U anti‐Xa/kg BW (actual range 63 to 91) once daily started 12 hours before operation
Number of subjects: 250
Study 10726050 — intervention group
Group type: COMPARATOR
Intervention: 50 U anti‐Xa/kg BW (actual range 41 to 71) once daily started 2 hours before operation
Number of subjects: 250
Study 9374602 — intervention group
Group type: EXPERIMENTAL
Intervention: Confessions
Number of subjects: 0
Study 9374602 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyewitness identification
Number of subjects: 0
Study 9374602 — intervention group
Group type: EXPERIMENTAL
Intervention: Character testimony
Number of subjects: 0
Study 9374602 — intervention group
Group type: COMPARATOR
Intervention: No evidence
Number of subjects: 0
Study 1439060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (active treatment)
Number of subjects: 0
Study 1439060 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum (placebo)
Number of subjects: 0
Study 1439060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (active treatment)
Number of subjects: 0
Study 1439060 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (placebo)
Number of subjects: 0
Study 3803821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 200 mg daily for 2 months
Number of subjects: 38
Study 3803821 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 38
Study 31092661 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational distress (psychiatric morbidity, burnout, job effort, work-life imbalance, coping with stress through self-blame or substances)
Number of subjects: 417
Study 31092661 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational distress
Number of subjects: 417
Study 31092661 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout
Number of subjects: 417
Study 30107809 — intervention group
Group type: EXPERIMENTAL
Intervention: Milestones Communication Approach (MCA)
Number of subjects: 100
Study 26920137 — intervention group
Group type: EXPERIMENTAL
Intervention: NOVOCART™ Disc plus autologous disc chondrocyte transplantation
Number of subjects: 120
Study 25061313 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren-based therapy
Number of subjects: 154
Study 25061313 — intervention group
Group type: COMPARATOR
Intervention: Ramipril-based therapy
Number of subjects: 154
Study 21862331 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus trastuzumab (Arm B)
Number of subjects: 92
Study 21862331 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (Arm A)
Number of subjects: 92
Study 21862331 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (Arm C)
Number of subjects: 92
Study 19574783 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 AS04-adjuvanted vaccine
Number of subjects: 0
Study 18160685 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator implantation plus adjunctive catheter ablation
Number of subjects: 128
Study 18160685 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator implantation alone
Number of subjects: 128
Study 15724802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 16
Study 15724802 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 16
Study 12479190 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI at 19 ng x ml(‐1) reduced to 10 ng x ml(‐1) after 1 min
Number of subjects: 60
Study 12479190 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI at 15 ng x ml(‐1) reduced to 8 ng x ml(‐1) after 1 min
Number of subjects: 60
Study 12479190 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI at 11 ng x ml(‐1) reduced to 6 ng x ml(‐1) after 1 min
Number of subjects: 60
Study 12479190 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI at 6.5 microg x ml(‐1) reduced to 3 microg x ml(‐1) after 1 min
Number of subjects: 60
Study 12479190 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-laryngoscopy measurements
Number of subjects: 60
Study 9716198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailout coronary stenting
Number of subjects: 50
Study 7926230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1500 mg
Number of subjects: 39
Study 7926230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg
Number of subjects: 39
Study 2513859 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40
Study 2513859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1099263 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16
Study 1099263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16
Study 1099263 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + Ephedrine
Number of subjects: 16
Study 1099263 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + Ephedrine + Hydroxyzine
Number of subjects: 16
Study 1099263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 16
Study 1099263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30998547 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong signal processing hearing aid fitting
Number of subjects: 49
Study 30998547 — intervention group
Group type: COMPARATOR
Intervention: Mild signal processing hearing aid fitting
Number of subjects: 49
Study 28512047 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted lateral entry point approach
Number of subjects: 68
Study 28512047 — intervention group
Group type: COMPARATOR
Intervention: Traditional transpedicle approach
Number of subjects: 68
Study 25381471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute group (3-7 weeks post-injury)
Number of subjects: 55
Study 25381471 — intervention group
Group type: COMPARATOR
Intervention: Chronic group (6-11 months post-injury)
Number of subjects: 55
Study 23455863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal bridle
Number of subjects: 50